On the other hand, long-term prognosis and therapeutic options are much poorer in triple-negative breast cancers (TNBC), which by definition do not express ERα and progesterone receptor (PR), and do not overexpress the receptor tyrosine-protein kinase erbB-2 (HER2). The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.